1. Home
  2. CGON vs AMPH Comparison

CGON vs AMPH Comparison

Compare CGON & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • AMPH
  • Stock Information
  • Founded
  • CGON 2010
  • AMPH 1996
  • Country
  • CGON United States
  • AMPH United States
  • Employees
  • CGON N/A
  • AMPH N/A
  • Industry
  • CGON
  • AMPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGON
  • AMPH Health Care
  • Exchange
  • CGON NYSE
  • AMPH Nasdaq
  • Market Cap
  • CGON 2.4B
  • AMPH 2.5B
  • IPO Year
  • CGON 2024
  • AMPH 2014
  • Fundamental
  • Price
  • CGON $28.45
  • AMPH $39.45
  • Analyst Decision
  • CGON Strong Buy
  • AMPH Buy
  • Analyst Count
  • CGON 8
  • AMPH 4
  • Target Price
  • CGON $63.88
  • AMPH $60.33
  • AVG Volume (30 Days)
  • CGON 819.4K
  • AMPH 476.9K
  • Earning Date
  • CGON 02-02-2025
  • AMPH 11-06-2024
  • Dividend Yield
  • CGON N/A
  • AMPH N/A
  • EPS Growth
  • CGON N/A
  • AMPH 17.38
  • EPS
  • CGON N/A
  • AMPH 3.01
  • Revenue
  • CGON $684,000.00
  • AMPH $723,549,000.00
  • Revenue This Year
  • CGON $165.75
  • AMPH $16.86
  • Revenue Next Year
  • CGON $47.04
  • AMPH $10.07
  • P/E Ratio
  • CGON N/A
  • AMPH $13.11
  • Revenue Growth
  • CGON 258.12
  • AMPH 20.33
  • 52 Week Low
  • CGON $25.77
  • AMPH $36.56
  • 52 Week High
  • CGON $50.23
  • AMPH $65.92
  • Technical
  • Relative Strength Index (RSI)
  • CGON 31.50
  • AMPH 27.22
  • Support Level
  • CGON $27.58
  • AMPH $43.34
  • Resistance Level
  • CGON $36.73
  • AMPH $45.39
  • Average True Range (ATR)
  • CGON 2.01
  • AMPH 1.38
  • MACD
  • CGON -0.52
  • AMPH -0.33
  • Stochastic Oscillator
  • CGON 9.51
  • AMPH 9.14

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: